Abstract
This Article argues that there is a prevailing problem of access to genetic invention in Canada caused by disputes over intellectual property rights arising from conflicting normative orders.
Keywords
Patents -- Canada, Genetics, Health care industry -- Canada, Health care industry -- Law & legislation, Gene therapy, Generic drugs, Health care services accessibility, Patent licensing, Bayh-Dole Act, Canada, United States